(Q39632395)

13 September 2017

title

Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? (English)

1 reference

13 September 2017

Paul C McDonald

1

1 reference

13 September 2017

Janet E Wilson

2

1 reference

13 September 2017

Min Gao

3

1 reference

13 September 2017

Shannon McNeill

4

1 reference

13 September 2017

John J Spinelli

5

1 reference

13 September 2017

O Dale Williams

6

1 reference

13 September 2017

Salima Harji

7

1 reference

13 September 2017

Jennifer Kenyon

8

1 reference

13 September 2017

Bruce M McManus

9

1 reference

13 September 2017

publication date

1 September 2002

1 reference

13 September 2017

published in

Cardiovascular Pathology

1 reference

13 September 2017

volume

11

1 reference

13 September 2017

issue

5

1 reference

13 September 2017

page(s)

251-262

1 reference

Valvular heart disease associated with fenfluramine-phentermine

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

The progression of fenfluramine-associated valvular heart disease assessed by echocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

The fen-phen controversy: is regression another piece of the puzzle?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Histologic changes in three explanted native cardiac valves following use of fenfluramines

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Endocardial fibrosis associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

The challenge of defining normality for human mitral and aortic valves: geometrical and compositional analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Surgical pathology of the mitral valve: a study of 712 cases spanning 21 years

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Cardiovascular complications of malignant carcinoid disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

A unique heart disease associated with a unique cancer: carcinoid heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

THE AGING HEART. II. THE VALVES

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

Etiology of valvular heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

1 reference

7 January 2021

Histochemical and immunohistochemical morphology of carcinoid heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-8807%2802%2900110-2

7 January 2021

10.1016/S1054-8807(02)00110-2

Identifiers

DOI

1 reference

13 September 2017

1 reference